clinical trial · NCT06674915
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment
Chengdu Suncadia Medicine Co., Ltd.·phase1·completed·n = 24
Complement Mediated Primary or Secondary Glomerular DiseasesHRS-5965 capsules
brief summary
The study is being conducted to compare the pharmacokinetics, safety, and pharmacodynamics of HRS-5965 in subjects with mild to moderate hepatic impairment and normal hepatic function.
started
Nov 26, 2024
primary completion
Jan 16, 2026
completion
Jan 16, 2026
last updated
Jan 30, 2026
official title
A Single-dose, Open-label, Phase I Study Comparing the Pharmacokinetics, Safety, and Pharmacodynamics of HRS-5965 in Subjects With Mild and Moderate Hepatic Impairment and Normal Hepatic Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol